Menopur (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). FSH binds to receptors on ovarian granulosa cells to recruit and grow follicles, while LH activates receptors on theca and Leydig cells, triggering final maturation, ovulation, and testosterone synthesis, thereby facilitating gamete development in both sexes.

The dose of Menopur is individualized and determined by the prescribing clinician based on the patient’s response, treatment protocol, and monitoring results. Specific dosing regimens are not standardized and should be set by a qualified healthcare professional.

Menopur is not indicated for use during an established pregnancy and should only be administered after confirming a non‑pregnant status. Safety data for breastfeeding are limited, and the product is generally avoided in lactating women unless the benefits outweigh potential risks as assessed by a physician.

To order Menopur, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Menopur is a urinary‑derived menotropin containing both FSH and LH activity, whereas many alternatives are recombinant forms that provide only FSH (e.g., follitropin alfa) or separate recombinant LH. Menopur offers combined activity in a single preparation, which can simplify dosing but may have slightly different immunogenicity and cost profiles compared with recombinant products.

Menopur should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. After reconstitution, the solution should be used promptly according to the product’s stability guidelines and any remaining material discarded if not used within the specified time frame.

Menopur is supplied as a lyophilized powder that must be reconstituted with the provided diluent. The resulting solution is administered by subcutaneous injection, typically in the abdominal wall or thigh, following the dosing schedule prescribed by the treating specialist.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, shortness of breath, and electrolyte disturbances, as well as thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, and rare but potentially life‑threatening allergic reactions like anaphylaxis.

Menopur is contraindicated in individuals with known hypersensitivity to menotropin or any component of the formulation, in patients with uncontrolled thyroid disease, in those with estrogen‑dependent neoplasms unless benefits outweigh risks, and in pregnant women. It should also be used with caution in patients with severe ovarian cysts or a history of thromboembolic disorders.